Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges
Annenberg Center for Health Sciences
1 episodes
5 days ago
An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.
All content for Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.
Solving Practice Challenges in Community-Based Interprofessional Care Teams
Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges
49 minutes 48 seconds
1 year ago
Solving Practice Challenges in Community-Based Interprofessional Care Teams
In this 1-hour, online activity, lymphoma expert Jeremy Abramson, MD, shares his experience navigating these challenges as part of an interprofessional, multidisciplinary care team.
Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges
An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.
